Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter

Drug and Alcohol Dependence

Volumn 147, Issue , 2015, Pages 1-19

  Reith, Maarten E A ^a   Blough, Bruce E ^b   Hong, Weimin C ^c   Jones, Kymry T ^a   Schmitt, Kyle C ^a   Baumann, Michael H ^c   Partilla, John S ^c   Rothman, Richard B ^c   Katz, Jonathan L ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Atypical effects; DA releasers; DAT inhibitors; Dopamine transporter; Molecular mechanisms; Stimulant abuse treatment compounds

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BENZATROPINE; CANNABINOID 1 RECEPTOR; CHOLESTEROL; COCAINE; DELTA OPIATE RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; JHW 007; MODAFINIL; RIMCAZOLE; RTI 336; RTI 371; SEROTONIN; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; VANOXERINE; VESICULAR MONOAMINE TRANSPORTER 2; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; LIGAND; PROTEIN BINDING;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; COCAINE DEPENDENCE; CRYSTAL STRUCTURE; DISCRIMINATIVE STIMULUS; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; DROSOPHILA; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; METHAMPHETAMINE DEPENDENCE; NEUROTRANSMISSION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; REVIEW; SEROTONIN RELEASE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; PHYSIOLOGY; PROCEDURES; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

BACTERIA (MICROORGANISMS);

ANIMALS; BENZHYDRYL COMPOUNDS; BENZTROPINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84921060790     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.12.005     Document Type: Review

References (141)

1. Adkins E.M., Samuvel D.J., Fog J.U., Eriksen J., Jayanthi L.D., Vaegter C.B., Ramamoorthy S., Gether U. Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 2007, 46:10484-10497.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Arlington, VA. fifth ed.
3. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
4. Banks M.L., Blough B.E., Fennell T.R., Snyder R.W., Negus S.S. Effects of phendimetrazine treatment on cocaine vs food choice and extended-access cocaine consumption in rhesus monkeys. Neuropsychopharmacology 2013, 38:2698-2707.
5. Banks M.L., Blough B.E., Fennell T.R., Snyder R.W., Negus S.S. Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. Drug Alcohol Depend. 2013, 130:158-166.
6. Banks M.L., Blough B.E., Negus S.S. Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys. Drug Alcohol Depend. 2013, 131:204-213.
7. Barrett A.C., Miller J.R., Dohrmann J.M., Caine S.B. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 2004, 47(Suppl. 1):256-273.
8. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000, 36:102-113.
9. Baumann M.H., Clark R.D., Woolverton W.L., Wee S., Blough B.E., Rothman R.B. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J. Pharmacol. Exp. Ther. 2011, 337:218-225.
10. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 1989, 251:150-155.
11. Bergman J., Spealman R.D. Some behavioral effects of histamine H1 antagonists in squirrel monkeys. J. Pharmacol. Exp. Ther. 1986, 239:104-110.
12. Blough B.E., Landavazo A., Partilla J.S., Baumann M.H., Decker A.M., Page K.M., Rothman R.B. Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. ACS Med. Chem. Lett. 2014, 5:623-627.
13. Bulling S., Schicker K., Zhang Y.W., Steinkellner T., Stockner T., Gruber C.W., Boehm S., Freissmuth M., Rudnick G., Sitte H.H., Sandtner W. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J. Biol. Chem. 2012, 287:18524-18534.
14. Butcher S.P., Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 1988, 50:346-355.
15. Campbell V.C., Kopajtic T.A., Newman A.H., Katz J.L. Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J. Pharmacol. Exp. Ther. 2005, 315:631-640.
16. Cao J., Prisinzano T.E., Okunola O.M., Kopajtic T., Shook M., Katz J.L., Newman A.H. Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues. ACS Med. Chem. Lett. 2010, 2:48-52.
17. Carlton P.L., Didamo P. Augmentation of the behavioral effects of amphetamine by atropine. J. Pharmacol. Exp. Ther. 1961, 132:91-96.
18. Carroll F.I., Lewin A.H., Mascarella S.W. Dopamine transporter uptake blockers. Structure-activity relationships. Neurotransmitter Transporters: Structure, Function, and Regulation 2002, 381-432. Humana Press, Totowa, NJ. M.E.A. Reith (Ed.).
19. Carroll F.I., Blough B.E., Abraham P., Mills A.C., Holleman J.A., Wolckenhauer S.A., Decker A.M., Landavazo A., McElroy K.T., Navarro H.A., Gatch M.B., Forster M.J. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 2009, 52:6768-6781.
20. Carroll F.I., Pawlush N., Kuhar M.J., Pollard G.T., Howard J.L. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes. J. Med. Chem. 2004, 47:296-302.
21. Cervinski M.A., Foster J.D., Vaughan R.A. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J. Biol. Chem. 2005, 280:40442-40449.
22. Chen N., Ferrer J.V., Javitch J.A., Justice J.B. Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J. Biol. Chem. 2000, 275:1608-1614.
23. Chen N., Justice J.B. Cocaine acts as an apparent competitive inhibitor at the outward-facing conformation of the human norepinephrine transporter: kinetic analysis of inward and outward transport. J. Neurosci. 1998, 18:10257-10268.
24. Chen N., Zhen J., Reith M.E.A. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR 12909 and benztropine as opposed to cocaine. J. Neurochem. 2004, 89:853-864.
25. Cremona M.L., Matthies H.J., Pau K., Bowton E., Speed N., Lute B.J., Anderson M., Sen N., Robertson S.D., Vaughan R.A., Rothman J.E., Galli A., Javitch J.A., Yamamoto A. Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat. Neurosci. 2011, 14:469-477.
26. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
27. Dackis C.A., Kampman K.M., Lynch K.G., Plebani J.G., Pettinati H.M., Sparkman T., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J. Subst. Abuse Treat. 2012, 43:303-312.
28. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., Rowan A., Poole S., White L., O'Brien C.P. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003, 70:29-37.
29. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 2002, 290:1545-1550.
30. Desai R.I., Grandy D.K., Lupica C.R., Katz J.L. Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J. Pharmacol. Exp. Ther. 2014, 348:106-115.
31. Desai R.I., Kopajtic T.A., Koffarnus M., Newman A.H., Katz J.L. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 2005, 25:1889-1893.
32. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
33. Florin S.M., Kuczenski R., Segal D.S. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 1995, 274:231-241.
34. Foster J.D., Adkins S.D., Lever J.R., Vaughan R.A. Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J. Neurochem. 2008, 105:1683-1699.
35. Gerlach K.K., Dasgupta N., Schnoll S.H., Henningfield J.E. Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research. Neuropharmacology 2014, 87C:91-96.
36. Gold L.H., Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berlin) 1996, 126:286-292.
37. Gowrishankar R., Hahn M.K., Blakely R.D. Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders. Neurochem. Int. 2014, 73:42-48.
38. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 2001, 21:522-526.
39. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 2004, 29:1439-1464.
40. Gundlah C., Hjorth S., Auerbach S.B. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology 1997, 36:475-482.
41. Haile C.N., Zhang X.Y., Carroll F.I., Kosten T.A. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res. 2005, 1055:186-195.
42. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
43. Hiranita T., Kohut S.J., Soto P.L., Tanda G., Kopajtic T.A., Katz J.L. Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 2014, 348:174-191.
44. Hiranita T., Soto P.L., Kohut S.J., Kopajtic T., Cao J., Newman A.H., Tanda G., Katz J.L. Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors. J. Pharmacol. Exp. Ther. 2011, 339:662-677.
45. Hiranita T., Soto P.L., Newman A.H., Katz J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther. 2009, 329:677-686.
46. Hiranita T., Wilkinson D.S., Hong W.C., Zou M.F., Kopajtic T.A., Soto P.L., Lupica C.R., Newman A.H., Katz J.L. 2-Isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. J. Pharmacol. Exp. Ther. 2014, 349:297-309.
47. Hong W.C., Amara S.G. Membrane cholesterol modulates the outward-facing conformation of the dopamine transporter and alters cocaine binding. J. Biol. Chem. 2010, 285:32616-32626.
48. Howell L.L., Carroll F.I., Votaw J.R., Goodman M.M., Kimmel H.L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 320:757-765.
49. Howell L.L., Negus S.S. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv. Pharmacol. 2014, 69:129-176.
50. Izenwasser S., Newman A.H., Katz J.L. Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur. J. Pharmacol. 1993, 243:201-205.
51. Jacobs M.T., Zhang Y.W., Campbell S.D., Rudnick G. Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. J. Biol. Chem. 2007, 282:29441-29447.
52. Johnston L.D., O'Malley P.M., Miech R.A., Bachman J.G., Schulenberg J.E. Monitoring the Future, National Survey Results on Drug Use 1975-2013: 2013 Overview, Key Findings on Adolescent Drug Use 2014, Institute for Social Research, The University of Michigan, Ann Arbor, Michigan.
53. Jones K.T., Zhen J., Reith M.E.A. Importance of cholesterol in dopamine transporter function. J. Neurochem. 2012, 123:700-715.
54. Karila L., Reynaud M. Therapeutic approaches to cocaine addiction. Rev. Prat. 2009, 59:830-834.
55. Katz J.L., Agoston G.E., Alling K.L., Kline R.H., Forster M.J., Woolverton W.L., Kopajtic T.A., Newman A.H. Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology (Berlin) 2001, 154:362-374.
56. Katz J.L., Izenwasser S., Kline R.H., Allen A.C., Newman A.H. Novel 3alpha-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J. Pharmacol. Exp. Ther. 1999, 288:302-315.
57. Katz J.L., Izenwasser S., Terry P. Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology (Berlin) 2000, 148:90-98.
58. Katz J.L., Kopajtic T.A., Agoston G.E., Newman A.H. Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J. Pharmacol. Exp. Ther. 2004, 309:650-660.
59. Katz J.L., Su T.P., Hiranita T., Hayashi T., Tanda G., Kopajtic T., Tsai S.Y. A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals (Basel) 2011, 4:880-914.
60. Khoshbouei H., Sen N., Guptaroy B., Johnson L., Lund D., Gnegy M.E., Galli A., Javitch J.A. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2004, 2:E78.
61. Khoshbouei H., Wang H., Lechleiter J.D., Javitch J.A., Galli A. Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J. Biol. Chem. 2003, 278:12070-12077.
62. Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., Uhl G.R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:7782-7785.
63. Kohut S.J., Hiranita T., Hong S.K., Ebbs A.L., Tronci V., Green J., Garces-Ramirez L., Chun L.E., Mereu M., Newman A.H., Katz J.L., Tanda G. Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine. Biol. Psychiatry 2014, pii: S0006-3223(14)00266-2. (Epub ahead of print). 10.1016/j.biopsych.2014.03.031.
64. Kopajtic T.A., Liu Y., Surratt C.K., Donovan D.M., Newman A.H., Katz J.L. Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J. Pharmacol. Exp. Ther. 2010, 335:703-714.
65. Krishnamurthy H., Gouaux E. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 2012, 481:469-474.
66. Leviel V. Dopamine release mediated by the dopamine transporter, facts and consequences. J. Neurochem. 2011, 118:475-489.
67. Li S.M., Kopajtic T.A., O'Callaghan M.J., Agoston G.E., Cao J., Newman A.H., Katz J.L. N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J. Pharmacol. Exp. Ther. 2011, 336:575-585.
68. Llosa T., Llosa L. Handbook on Oral Cocaine as an Agonist Therapy in Cocaine Dependence 2005, (accessed 10.15.14). http://www.bvcedro.org.pe/bitstream/123456789/415/1/833-BRCM-S-COCA.pdf.
69. Loland C.J., Desai R.I., Zou M.F., Cao J., Grundt P., Gerstbrein K., Sitte H.H., Newman A.H., Katz J.L., Gether U. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol. Pharmacol. 2008, 73:813-823.
70. Loland C.J., Mereu M., Okunola O.M., Cao J., Prisinzano T.E., Mazier S., Kopajtic T., Shi L., Katz J.L., Tanda G., Newman A.H. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol. Psychiatry 2012, 72:405-413.
71. Malcolm R., Swayngim K., Donovan J.L., DeVane C.L., Elkashef A., Chiang N., Khan R., Mojsiak J., Myrick D.L., Hedden S., Cochran K., Woolson R.F. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 2006, 32:577-587.
72. Martin-Fardon R., Maurice T., Aujla H., Bowen W.D., Weiss F. Differential effects of sigma1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacology 2007, 32:1967-1973.
73. Matsumoto R.R. Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev. Clin. Pharmacol. 2009, 2:351-358.
74. Mello N.K., Negus S.S. Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine+heroin) self-administration by rhesus monkeys. Neuropsychopharmacology 2007, 32:1985-1994.
75. Mereu M., Bonci A., Newman A.H., Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berlin) 2013, 229:415-434.
76. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
77. Mooney M.E., Herin D.V., Schmitz J.M., Moukaddam N., Green C.E., Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009, 101:34-41.
78. Navarro H.A., Howard J.L., Pollard G.T., Carroll F.I. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br. J. Pharmacol. 2009, 156:1178-1184.
79. Negus S.S., Baumann M.H., Rothman R.B., Mello N.K., Blough B.E. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine (+)phenmetrazine, and 4-benzylpiperidine. J. Pharmacol. Exp. Ther. 2009, 329:272-281.
80. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend. 2003, 70:39-52.
81. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 320:627-636.
82. Newman J.L., Negus S.S., Lozama A., Prisinzano T.E., Mello N.K. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp. Clin. Psychopharmacol. 2010, 18:395-408.
83. O'Brien C.P. Modafinil-cocaine interactions: clinical implications. Biol. Psychiatry 2012, 72:346.
84. Partilla J.S., Dempsey A.G., Nagpal A.S., Blough B.E., Baumann M.H., Rothman R.B. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 2006, 319:237-246.
85. Penmatsa A., Wang K.H., Gouaux E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 2013, 503:85-90.
86. Phillips K.A., Epstein D.H., Preston K.L. Psychostimulant addiction treatment. Neuropharmacology 2014, (April). pii: S0028-3908(14)00128-2. (Epub ahead of print). 10.1016/j.neuropharm.2014.04.002.
87. Pontieri F.E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the shell as compared with the core of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:12304-12308.
88. Quick M., Shi L., Zehnpfennig B., Weinstein H., Javitch J.A. Experimental conditions can obscure the second high-affinity site in LeuT. Nat. Struct. Mol. Biol. 2012, 19:207-211.
89. Raje S., Cao J., Newman A.H., Gao H., Eddington N.D. Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J. Pharmacol. Exp. Ther. 2003, 307:801-808.
90. Rea W.P., Rothman R.B., Shippenberg T.S. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: concordance with clinical studies. Synapse 1998, 30:107-111.
91. Reith M.E.A., Ali S., Hashim A., Sheikh I.S., Theddu N., Gaddiraju N.V., Mehrotra S., Schmitt K.C., Murray T.F., Sershen H., Unterwald E.M., Davis F.S. Novel C-1 substituted cocaine analogues unlike cocaine or benztropine. J. Pharmacol. Exp. Ther. 2012, 343:413-425.
92. Reith M.E.A., Berfield J.L., Wang L.C., Ferrer J.V., Javitch J.A. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J. Biol. Chem. 2001, 276:29012-29018.
93. Reith M.E.A., Coffey L.L. Structure-activity relationships for cocaine congeners in inhibiting dopamine uptake into rat brain synaptic vesicles and bovine chromaffin granule ghosts. J. Pharmacol. Exp. Ther. 1994, 271:1444-1452.
94. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
95. Rothman R.B., Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 2002, 95:73-88.
96. Rothman R.B., Baumann M.H., Blough B.E., Jacobson A.E., Rice K.C., Partilla J.S. Evidence for noncompetitive modulation of substrate-induced serotonin release. Synapse 2010, 64:862-869.
97. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
98. Rothman R.B., Becketts K.M., Radesca L.R., De Costa B.R., Rice K.C., Carroll F.I., Dersch C.M. Studies of the biogenic amine transporters II. A brief study on the use of [3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci. 1993, 53:L267-L272.
99. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., Roth B.L., Baumann M.H. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 2005, 313:1361-1369.
100. Rothman R.B., Elmer G.I., Shippenberg T.S., Rea W., Baumann M.H. Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. Ann. N. Y. Acad. Sci. 1998, 844:59-74.
101. Rothman R.B., Katsnelson M., Vu N., Partilla J.S., Dersch C.M., Blough B.E., Baumann M.H. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur. J. Pharmacol. 2002, 447:51-57.
102. Rothman R.B., Partilla J.S., Baumann M.H., Lightfoot-Siordia C., Blough B.E. Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters. J. Pharmacol. Exp. Ther. 2012, 341:251-262.
103. Scheckel C.L., Boff E. Behavioral effects of interacting imipramine and other drugs with d-amphetamine, cocaine, and tetrabenazine. Psychopharmacologia 1964, 5:198-208.
104. Schenk S. Effects of GBR 12909, WIN 35,428 and indatraline on cocaine self-administration and cocaine seeking in rats. Psychopharmacology (Berlin) 2002, 160:263-270.
105. Schmitt K.C., Reith M.E.A. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS ONE 2011, 6:e25790.
106. Schmitt K.C., Rothman R.B., Reith M.E.A. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J. Pharmacol. Exp. Ther. 2013, 346:2-10.
107. Seddik A., Holy M., Weissensteiner R., Zdrazil B., Sitte H.H., Ecker G.F. Probing the selectivity of monoamine transporter substrates by means of molecular modeling. Mol. Inform. 2013, 32:409-413.
108. Severinsen K., Kraft J.F., Koldso H., Vinberg K.A., Rothman R.B., Partilla J.S., Wiborg O., Blough B., Schiott B., Sinning S. Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. ACS Chem. Neurosci. 2012, 3:693-705.
109. Shi L., Quick M., Zhao Y., Weinstein H., Javitch J.A. The mechanism of a neurotransmitter:sodium symporter - inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol. Cell 2008, 30:667-677.
110. Singh S.K., Piscitelli C.L., Yamashita A., Gouaux E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 2008, 322:1655-1661.
111. Singh S.K., Yamashita A., Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 2007, 448:952-956.
112. Sitte H.H., Freissmuth M. The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters - why amphetamines take two to tango. J. Neurochem. 2010, 112:340-355.
113. Sitte H.H., Huck S., Reither H., Boehm S., Singer E.A., Pifl C. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem. 1998, 71:1289-1297.
114. Sonders M.S., Zhu S.J., Zahniser N.R., Kavanaugh M.P., Amara S.G. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 1997, 17:960-974.
115. Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 2011, 69:628-649.
116. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
117. Tanda G. Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. Pharmacol. Res. 2007, 56:406-417.
118. Tanda G., Ebbs A., Newman A.H., Katz J.L. Effects of 4'-chloro-3 alpha-(diphenylmethoxy)-tropane on mesostriatal, mesocortical, and mesolimbic dopamine transmission: comparison with effects of cocaine. J. Pharmacol. Exp. Ther. 2005, 313:613-620.
119. Tanda G., Ebbs A.L., Kopajtic T.A., Elias L.M., Campbell B.L., Newman A.H., Katz J.L. Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats. J. Pharmacol. Exp. Ther. 2007, 321:334-344.
120. Tanda G., Kopajtic T.A., Katz J.L. Cocaine-like neurochemical effects of antihistaminic medications. J. Neurochem. 2008, 106:147-157.
121. Tanda G., Li S.M., Mereu M., Thomas A.M., Ebbs A.L., Chun L.E., Tronci V., Green J.L., Zou M.F., Kopajtic T.A., Newman A.H., Katz J.L. Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change. Psychopharmacology (Berlin) 2013, 229:307-321.
122. Tanda G., Newman A.H., Katz J.L. Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv. Pharmacol. 2009, 57:253-289.
123. Tanda G., Pontieri F.E., Di C.G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
124. Teng L., Crooks P.A., Dwoskin L.P. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 1998, 71:258-265.
125. Tuomisto J., Tuomisto L. Effects of histamine and histamine antagonists on the uptake and release of catecholamines and 5-HT in brain synaptosomes. Med. Biol. 1980, 58:33-37.
126. Ukairo O.T., Bondi C.D., Newman A.H., Kulkarni S.S., Kozikowski A.P., Pan S., Surratt C.K. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J. Pharmacol. Exp. Ther. 2005, 314:575-583.
127. Valchar M., Hanbauer I. Comparison of [3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J. Neurochem. 1993, 60:469-476.
128. Vosburg S.K., Hart C.L., Haney M., Rubin E., Foltin R.W. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend. 2010, 106:233-236.
129. Wang H., Goehring A., Wang K.H., Penmatsa A., Ressler R., Gouaux E. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 2013, 503:141-145.
130. Watanabe S., Aono Y., Fusa K., Takada K., Saigusa T., Koshikawa N., Cools A.R. Contribution of vesicular and cytosolic dopamine to the increased striatal dopamine efflux elicited by intrastriatal injection of dexamphetamine. Neuroscience 2005, 136:251-257.
131. Wee S., Anderson K.G., Baumann M.H., Rothman R.B., Blough B.E., Woolverton W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther. 2005, 313:848-854.
132. Wojnicki F.H., Rothman R.B., Rice K.C., Glowa J.R. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey. J. Pharmacol. Exp. Ther. 1999, 288:550-560.
133. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry 2000, 47:818-829.
134. Woolverton W.L., Hecht G.S., Agoston G.E., Katz J.L., Newman A.H. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology (Berlin) 2001, 154:375-382.
135. Woolverton W.L., Rowlett J.K., Wilcox K.M., Paul I.A., Kline R.H., Newman A.H., Katz J.L. 3'- and 4'-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys. Psychopharmacology (Berlin) 2000, 147(January):426-435.
136. Yamashita A., Singh S.K., Kawate T., Jin Y., Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 2005, 437:215-223.
137. Yu H., Rothman R.B., Dersch C.M., Partilla J.S., Rice K.C. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg. Med. Chem. 2000, 8:2689-2692.
138. Zahniser N.R., Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction?. Neuropharmacology 2004, 47(Suppl. 1):80-91.
139. Zhou Z., Zhen J., Karpowich N.K., Goetz R.M., Law C.J., Reith M.E.A., Wang D.N. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007, 317:1390-1393.
140. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E.A., Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 2009, 16:652-657.
141. Zou M.F., Kopajtic T., Katz J.L., Newman A.H. Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes at the dopamine transporter. J. Med. Chem. 2003, 46:2908-2916.